Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Le on the Emergence of Antibody-Drug Conjugates in NSCLC

November 15th 2021

Xiuning Le, MD, PhD, discusses the emergence of antibody-drug conjugates in non–small cell lung cancer.

Dr. Patel Discusses Novel Targets in NSCLC

November 15th 2021

Sandip P. Patel, MD, discusses novel targets in non–small cell lung cancer.

Prospective Biomarkers of Pembrolizumab Combo Response Show Feasibility in Frontline Advanced NSCLC

November 15th 2021

T-cell inflamed gene expression profile and tumor mutational burden assessment was found to be a feasible approach to study the clinical activity of 3 pembrolizumab-based combination regimens in treatment-naïve patients with advanced non–small cell lung cancer.

Sotorasib Approaches EU Approval for KRAS G12C–Mutated Advanced NSCLC

November 12th 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the conditional marketing authorization of sotorasib for the treatment of adult patients with advanced non–small cell lung cancer whose tumors harbor a KRAS G12C mutation and who have progressed after at least 1 prior line of systemic therapy.

Treating EGFR Exon 20 Insertions and HER2-Mutant NSCLC

November 12th 2021

Dr Vamsidhar Velcheti evaluates the use of mobocertinib in patients with EGFR exon 20 insertions, and Drs John V. Heymach and Sandip P. Patel discuss the treatment of HER2-mutant NSCLC.

Treatment of TKI-Refractory EGFR-Mutant NSCLC

November 12th 2021

Heather Wakelee, MD, and Stephen Liu, MD, review the treatment of TKI-refractory EGFR-mutant NSCLC.

Dr. Ivanick on the Diagnostic Role of Interventional Pulmonologists in Lung Cancer

November 11th 2021

Nathaniel Ivanick, MD, FCCP, discusses the role of interventional pulmonologists in advanced diagnostics in lung cancer.

Additional Studies with Antibody-Drug Conjugates in NSCLC

November 11th 2021

Two experts discuss additional studies with antibody-drug conjugates targeting non-small cell lung cancer and the impact of their data on therapeutic options for the disease.

Trilaciclib Possesses Potential to Reduce Burden of Chemotherapy-Induced Myelosuppression in ES-SCLC

November 11th 2021

The administration of trilaciclib prior to chemotherapy reduced chemotherapy-induced myelosuppression and the need for associated supportive care in patients with extensive-stage small cell lung cancer.

NSCLC: Mobocertinib for Patients With EGFR Exon 20 Insertion Mutations

November 11th 2021

Considerations for the FDA approval and practical use of mobocertinib in patients with EGFR exon 20 insertion mutations in NSCLC.

NSCLC: Amivantamab for Patients With EGFR Exon 20 Insertion Mutations

November 11th 2021

Considerations for the FDA approval and practical use of amivantamab in patients with EGFR exon 20 insertion mutations in non-small cell lung cancer.

Dr. Langer on the Need for Reflex Testing in NSCLC

November 10th 2021

Corey J. Langer, MD, discusses the need for reflex testing in patients with non–small cell lung cancer.

Dr. Lazar on Risk Stratification for Chemotherapy and Adjuvant Therapy in Lung Cancer

November 10th 2021

John F. Lazar, MD, discusses risk stratification for chemotherapy and adjuvant therapy in lung cancer.

Dr. Bordoni on the Utility of Adjuvant Osimertinib in ​EGFR-Mutant Lung Cancer

November 10th 2021

Rodolfo Bordoni, MD, discusses the utility of ​adjuvant osimertinib in lung cancer.

FDA Grants Fast Track Status to Bemcentinib Combo for STK11-Altered Advanced or Metastatic NSCLC

November 9th 2021

The FDA granted a fast track designation to the selective AXL inhibitor bemcentinib in combination with a PD-1/PD-L1 agent in the treatment of patients with STK11-altered advanced or metastatic non–small cell lung cancer without actionable mutations.

Enhanced Grasp of Oncogenic Drivers Leads to Expanded Treatment Options in NSCLC

November 9th 2021

An increased understanding of the biology of non–small cell lung cancer has led to a significant increase in therapeutic options for patients.

Rapid Readouts: 3-Year Overall Survival Update From the Phase 3 CASPIAN Study

November 9th 2021

Afshin Dowlati, MD, discusses data from the following presentation: “Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the Phase 3 CASPIAN study.” (Paz-Ares, ESMO 2021, LBA61)

Dr. Saxena on a Challenging Case of NSCLC

November 8th 2021

Ashish Saxena, MD, PhD, discusses a challenging case of a patient with non–small cell lung cancer.

Dr. Zauderer on the Importance of Optimizing Care in Mesothelioma

November 8th 2021

Marjorie G. Zauderer, MD, discusses the importance of optimizing care for patients with mesothelioma.

Overcoming Mechanisms of Resistance Remains at the Forefront for EGFR-Mutant NSCLC

November 8th 2021

Although next-generation TKIs have helped to overcome resistance in EGFR-mutated non–small cell lung cancer, a more complete understanding of resistance mechanisms may lead to the ability to overcome resistance to the next generation of these drugs.

NEXT PAGE
PREVIOUS PAGE